Although PARP7 may be poorly understood, its role in ovarian cancer as a MARylator of alpha-tubulin, leading to microtubule instability and cancer cell motility, indicates the possibility of its inhibition as a new avenue of PARP therapeutics [113]. Here, TIPARP is linked to cancer.